| You
are here: Home: BCU 1|2003: Nancy
Davidson, MD: Select Publications
Select Publications
Adjuvant endocrine therapy in premenopausal patients
Aebi S et al. Is chemotherapy alone adequate for young
women with oestrogen-receptor-positive breast cancer? Lancet
2000;355(9218):1869-74. Abstract
Baum M et al. Management of premenopausal women with early
breast cancer: Is there a role for goserelin? Proc ASCO
2001; Abstract
103.
Boccardo F et al. Cyclophosphamide, methotrexate, and fluorouracil
versus tamoxifen plus ovarian suppression as adjuvant treatment
of estrogen receptor-positive pre-/perimenopausal breast cancer
patients: Results of the Italian Breast Cancer Adjuvant Study Group
02 randomized trial. J Clin Oncol 2000;18:2718-27. Abstract
Celio L et al. Premenopausal breast cancer patients treated
with a gonadotropin-releasing hormone analog alone or in combination
with an aromatase inhibitor: A comparative endocrine study.
Anticancer Res 1999;19:2261-8. Abstract
Cheung KL et al. The combined use of goserelin and anastrozole
as second line endocrine therapy in premenopausal women with advanced
breast cancer - A study of its clinical and endocrine effects.
Proc ASCO 2001;
Abstract 1937.
Colleoni M et al. Early start of adjuvant chemotherapy
may improve treatment outcome for premenopausal breast cancer patients
with tumors not expressing estrogen receptors. The International
Breast Cancer Study Group. J Clin Oncol 2000;18(3):584-90.
Abstract
Davidson N et al. Effect of chemohormonal therapy in pre-menopausal,
node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology
Group phase III Intergroup trial (E5188, INT-0101). Proc
ASCO 1999; Abstract
249A, 67A.
Dowsett M et al. Vorozole results in greater estrogen
suppression than formestane in postmenopausal women and when added
to goserelin in premenopausal women with advanced breast cancer.
Breast Cancer Res Treat 1999;56:25-34. Abstract
Early Breast Cancer Trialists’ Collaborative Group. Ovarian
ablation for early breast cancer. Cochrane Database Syst
Rev 2000;CD000485. Abstract
Early Breast Cancer Trialists’ Collaborative Group.
Ovarian ablation in early breast cancer: Overview of the randomised
trials. Lancet 1996;348:1189-96. Abstract
Ejlertsen B et al. Comparable effect of ovarian ablation
(OA) and CMF chemotherapy in premenopausal hormone receptor positive
breast cancer patients (PRP). Proc ASCO 1999. Abstract
Forward D et al. Combined use of goserelin (Zoladex) and
anastrozole (Arimidex) in premenopausal women with metastatic breast
cancer (MBC). Proc ASCO 2000; Abstract
582.
Gnant M et al. Changes in bone mineral density caused
by anastrozole or tamoxifen in combination with goserelin (±
zoledronate) as adjuvant treatment for hormone receptor-positive
premenopausal breast cancer: Results of a randomized multicenter
trial. Breast Cancer Res Treat 2002; Abstract
12.
Goldhirsch A et al. Adjuvant therapy for very young women
with breast cancer: Need for tailored treatments. J Natl
Cancer Inst Monogr 2001;(30):44-51. Abstract
582.
Goss PE, Strasser K. Aromatase inhibitors in the treatment
and prevention of breast cancer. J Clin Oncol 2001;19:881-94.
Abstract
Hoffken K, Kath R. The role of LH-RH analogues in the
adjuvant and palliative treatment of breast cancer. Recent
Results Cancer Res 2000;153:61-70. Abstract
Houghton J et al. The ZIPP trial of adjuvant Zoladex in
premenopausal patients with early breast cancer: An update at five
years. Proc ASCO 2000;
Abstract 359.
Jakesz R. Comparison of adjuvant therapy with tamoxifen
and goserelin vs. CMF in premenopausal stage I and II hormone-responsive
breast cancer patients: Four-year results of Austrian Breast Cancer
Study Group (ABCSG) Trial 5. Proc ASCO 1999; Abstract
250.
Jakesz R et al. Chemotherapy versus hormonal adjuvant
treatment in premenopausal patients with breast cancer. Eur
J Cancer 2002;38(3):327-32. Abstract
Jakesz R et al. Randomized adjuvant trial of tamoxifen
and goserelin versus cyclophosphamide, methotrexate, and Fluorouracil:
Evidence for the superiority of treatment with endocrine blockade
in premenopausal patients with hormone-responsive breast cancer-austrian
breast and colorectal cancer study group trial 5. J Clin
Oncol 2002;20(24):4628-35. Abstract.
Jonat W et al. Goserelin versus cyclophosphamide, methotrexate,
and fluorouracil as adjuvant therapy in premenopausal patients with
node-positive breast cancer: The Zoladex Early Breast Cancer Research
Association Study. J Clin Oncol 2002;20(24):4621-7. Abstract.
Kaufmann M et al. Updated survival results from the Zebra
trial. Breast Cancer Res Treat 2002; Abstract
254.
Klijn JG et al. Combined tamoxifen and luteinizing hormone-releasing
hormone (LHRH) agonist versus LHRH agonist alone in premenopausal
advanced breast cancer: A meta-analysis of four randomized trials.
J Clin Oncol 2001;19:343-53. Abstract
Love RR et al. Oophorectomy and tamoxifen adjuvant therapy
in premenopausal Vietnamese and Chinese women with operable breast
cancer. J Clin Oncol 2002;20(10):2559-66. Abstract
Michaud LB, Buzdar AU. Complete estrogen blockade for
the treatment of metastatic and early stage breast cancer.
Drugs Aging 2000;16:261-71. Abstract
Michaud LB et al. Combination endocrine therapy in the
management of breast cancer. Oncologist 2001;6(6):538-46.
Abstract
Milla-Santos A et al. A randomized trial of goserelin
(Zoladex™) + tamoxifen versus goserelin + anastrozole (Arimidex™)
) in pre/perimenopausal patients with hormone dependent advanced
breast cancer. Breast Cancer Res Treat 2002;No abstract
available.
Muss HB. Factors used to select adjuvant therapy of breast
cancer in the United States: an overview of age, race, and socioeconomic
status. J Natl Cancer Inst Monogr 2001;(30):52-5. Abstract
289.
Parulekar W et al. Incidence and prognostic impact of
amenorrhea during adjuvant therapy in high risk premenopausal breast
cancer patients: Analysis of a National Cancer Institute of Canada
Clinical Trials Group (NCIC CTG) phase III study. Proc
ASCO 2001;
Abstract 97.
Recchia F et al. Goserelin as ovarian protection in the
adjuvant treatment of premenopausal breast cancer: A phase II pilot
study. Anticancer Drugs 2002;13(4):417-24. Abstract.
Sayer HG et al. Bone mineral density in premenopausal
patients in a randomized trial of adjuvant endocrine therapy (ZIPP-TRIAL).
Proc ASCO 2001; Abstract
96.
Sverrisdottir A et al. Premenopausal breast cancer: Chemotherapy
and endocrine therapy. Drugs 2002;62(14):2025-38. Abstract.
|
